07:55 AM EDT, 05/23/2024 (MT Newswires) -- Tango Therapeutics ( TNGX ) said Thursday it will discontinue developing its TNG348 program due to liver toxicity experienced by patients during clinical trials.

Patients remaining in the study for more than eight weeks exhibited liver function abnormalities, leading to the decision to terminate the program, Tango said.

TNG348 was being developed as a treatment for certain advanced cancers.

Shares of the company were down 12% in recent Thursday premarket activity.

Price: 6.50, Change: -0.89, Percent Change: -12.04